Advances in the treatment of tuberculosis.
The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug-resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.
Zhang
Y
Y
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. yzhang@jhsph.edu
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D005029:Ethylenediamines / Q000494:pharmacology; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy; D024841:Fluoroquinolones / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D009593:Nitroimidazoles / Q000494:pharmacology; D010080:Oxazoles / Q000494:pharmacology; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D016312:Treatment Refusal; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D015507:Drugs, Investigational; D005029:Ethylenediamines; D024841:Fluoroquinolones; C506841:N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles; C410767:pretomanid; D011718:Pyrazinamide; D000218:Adamantane; D007538:Isoniazid; D012293:Rifampin